title: Preclinical toxicological examination of a putative prostate cancer-specific 4-methyl-1-nitroacridine derivative in rodents.
abstract: Nitroacridines are potent DNA-binding and cytotoxic agents in cancer cells, but could not be developed clinically due to high systemic toxicities. We are developing a 1-nitroacridine derivative, 9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), as an effective chemotherapeutic agent for prostate cancer. C-1748 demonstrates high antitumor efficacy against human prostate cancer xenografts with markedly low mutagenicity and toxicity in dogs compared with its parent 9-(2'-hydroxyethylamino)-1-nitroacridine (C-857). A surprising feature of C-1748 is the 40-fold difference in 50% inhibitory concentration between DU145 prostate cancer and HL-60 leukemia cells. In this study, we report the preclinical toxicity study of a single acute dose of C-1748 in Copenhagen rats and BALB/c mice, intraperitoneally and intravenously for 24 h and 7 days. The effect of C-1748 on hematology, cardiac and liver enzymes, and renal electrolytes was assessed by blood and serum analysis. The LD50 (lethal dose, 50%) for C-1748 was 9 and 13.42 mg/kg compared with 2.2 and 3 mg/kg for C-857 intraperitoneally and intravenously, respectively, in mice. In Copenhagen rats, LD50 was 15 and 14.4 mg/kg intraperitoneally and intravenously, respectively, compared to 4 and 1.3 mg/kg for C-857. No changes in blood cell counts were observed, which were in the normal range for rodents. No changes were observed in clinical chemistries of enzymes such as aspartate aminotransferase, alkaline phosphatase and creatine phosphokinase, which were within the normal range of values. No genome alterations were seen in prostate cancer cell lines by comparative genomic hybridization together with a lack of systemic toxicity, making it a unique cancer cell-type-specific drug that needs further clinical evaluation for toxicity and synergy in combination chemotherapy regimens.
authors.affiliation: Department of Microbiology & Immunology, New York Medical College, Valhalla, New York 10595, USA.
authors.forename: Badithe T
authors.initials: BT
authors.lastname: Ashok
authors.forename: Kiranmayi
authors.initials: K
authors.lastname: Tadi
authors.forename: Venkata P S
authors.initials: VP
authors.lastname: Garikapaty
authors.forename: Yuangen
authors.initials: Y
authors.lastname: Chen
authors.forename: Qiang
authors.initials: Q
authors.lastname: Huang
authors.forename: Debabrata
authors.initials: D
authors.lastname: Banerjee
authors.forename: Jerzy
authors.initials: J
authors.lastname: Konopa
authors.forename: Raj K
authors.initials: RK
authors.lastname: Tiwari
mesh_terms: D000818:Animals; D001769:Blood / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects*; D007928:Lethal Dose 50; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009564:Nitracrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D009693:Nucleic Acid Hybridization; D011471:Prostatic Neoplasms / Q000188:drug therapy; D051381:Rats
chemical_list: C513812:9-(2'-hydroxyethylamino)-4-methyl-1-nitroacridine; D004273:DNA, Neoplasm; D009564:Nitracrine